PMID- 33535737
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20240215
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 45
IP  - 6
DP  - 2021 Nov
TI  - Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant 
      Recipients with Type 2 Diabetes Mellitus: A Retrospective Review.
PG  - 948-953
LID - 10.4093/dmj.2020.0180 [doi]
AB  - Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has 
      demonstrated effectiveness when combined with basal insulin. We examined whether 
      the efficacy of dulaglutide is comparable to that of prandial insulin in kidney 
      transplant (KT) recipients with type 2 diabetes mellitus (T2DM) undergoing 
      multiple daily insulin injection (MDI) therapy. Thirty-seven patients, who 
      switched from MDI therapy to basal insulin and dulaglutide, were retrospectively 
      analyzed. Changes in glycosylated hemoglobin (HbA1c) and fasting plasma glucose 
      (FPG) levels, body weight, and basal insulin dose were evaluated over 6 months. 
      Dulaglutide was comparable to three injections of prandial insulin in terms of 
      glycemic control (HbA1c 7.1% vs. 7.0%; 95% confidence interval [CI], -0.53 to 
      0.28; P=0.53). The basal insulin and dulaglutide combination resulted in a 
      reduction in FPG levels by 9.7 mg/dL (95% CI, 2.09 to 41.54; P=0.03), in body 
      weight by 4.9 kg (95% CI, 2.87 to 6.98; P<0.001), and in basal insulin dose by 
      9.52 IU (95% CI, 5.80 to 3.23; P<0.001). Once-weekly dulaglutide may be an 
      effective alternative for thrice-daily prandial insulin in KT recipients with 
      T2DM currently receiving MDI therapy.
FAU - Kim, Hwi Seung
AU  - Kim HS
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
AD  - Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
FAU - Lee, Jiwoo
AU  - Lee J
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
AD  - Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
FAU - Jung, Chang Hee
AU  - Jung CH
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
AD  - Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
FAU - Park, Joong-Yeol
AU  - Park JY
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
AD  - Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
FAU - Lee, Woo Je
AU  - Lee WJ
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
AD  - Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20210205
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Insulin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptides/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Immunoglobulin Fc Fragments/therapeutic use
MH  - Insulin
MH  - *Kidney Transplantation
MH  - *Recombinant Fusion Proteins/therapeutic use
MH  - Retrospective Studies
PMC - PMC8640157
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Dulaglutide
OT  - Insulin
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/02/05 06:00
MHDA- 2022/03/09 06:00
PMCR- 2021/11/01
CRDT- 2021/02/04 03:07
PHST- 2020/07/23 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/02/04 03:07 [entrez]
PHST- 2021/11/01 00:00 [pmc-release]
AID - dmj.2020.0180 [pii]
AID - dmj-2020-0180 [pii]
AID - 10.4093/dmj.2020.0180 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2021 Nov;45(6):948-953. doi: 10.4093/dmj.2020.0180. Epub 2021 
      Feb 5.